Opinion
Video
Author(s):
Urologists review clinical trials investigating new imaging options in kidney cancer, including the ZIRCON study looking at girentuximab.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal
Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma
Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC
Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Patient selection for cytoreductive nephrectomy in 2025
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
AI-based tool aims to optimize MRI use in prostate cancer diagnosis
PSMA-PET imaging product, Gozellix, launches on US market
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer